Abstract:In the published manuscript, "Activation of hypermethylated P2RY1 mitigates gastric cancer by promoting apoptosis and inhibiting proliferation. Yinggang Hua, Yanling Liu, Long Li and Guoyan Liu, Open Life Sciences. 2023;18(1): 20220078. https://doi.org/10.1515/biol-2022-0078," the authors have found an unintentional error made during preparation of Figure 2. The statement from the authors reads as follows: During our recent review of the experiments described in the article, we identified an issue. Specifically, in Figure 2 of the article, there is an error in the Western blot (WB) images of P-c-Jun and c-Jun. This error occurred during the figure preparation process, where the WB images of P-ERK1/2 and ERK1/2 were mistakenly placed in the positions for P-c-Jun and c-Jun, resulting in repeated images. Figure 1 in this letter highlights the erroneous information. Red box indicates the repeated images of P-c-Jun and c-Jun in Figure 2 of the article. Figure 2 presents the actual WB results for P-c-Jun and c-Jun (MRS2365 agonist and MRS2500 antagonist). (a and b) The WB results for P-c-Jun and c-Jun (MRS2365 agonist and MRS2500 antagonist). Our experimental results indicate that the protein level of P-c-Jun increases after stimulation of SGC-7901 cells with MRS2365 (agonist), suggesting the phosphorylation and activation of c-Jun in the signaling pathway. Based on these accurate and reliable experimental results, we have created a new version of Figure 2 from the original manuscript. The new Figure 2 (here as Figure 3) corrects the WB results for P-c-Jun and c-Jun (MRS2365 agonist and MRS2500 antagonist). The corrected image does not affect the core content and conclusions of the original paper. Corrected version of Figure 2 in the article. The authors admit the error and claim that this is an unintentional error that has nothing to do with academic misconduct and does not influence the conclusion of the publication. The authors apologize to the editor, the staffs of the journal, and the journal readers for the mistake and any inconvenience it caused. # These authors contributed equally to this work. © 2024 the author(s), published by De Gruyter This work is licensed under the Creative Commons Attribution 4.0 International License.

Author Correction: Synergistic Suppression of Human Breast Cancer Cells by Combination of Plumbagin and Zoledronic Acid in Vitro

Plumbagin Attenuates Cancer Cell Growth and Osteoclast Formation in the Bone Microenvironment of Mice

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Erratum: Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

[Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‐1 pathway inhibition in vivo

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

[Corrigendum] Nucleosome‐binding protein HMGN2 exhibits antitumor activity in human SaO2 and U2‐OS osteosarcoma cell lines

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

Correction To: Suppressive Effects of Plumbagin on Invasion and Migration of Breast Cancer Cells Via the Inhibition of STAT3 Signaling and Down-Regulation of Inflammatory Cytokine Expressions

Erratum to "Activation of hypermethylated P2RY1 mitigates gastric cancer by promoting apoptosis and inhibiting proliferation"

[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‐4 in vitro and in vivo

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

[Corrigendum] Inhibition of sphingosine-1-phosphate phosphatase 1 promotes cancer cells migration in gastric cancer: Clinical implications.

[Corrigendum] The cranberry flavonoids PAC DP‑9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells

[Corrigendum] Azurocidin 1 inhibits the aberrant proliferation of triple‐negative breast cancer through the regulation of pyroptosis

Correction: An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Correction: Corrigendum: Patient-specific Hepatocyte-Like Cells Derived from Induced Pluripotent Stem Cells Model Pazopanib-Mediated Hepatotoxicity